ArticleJournal of pharmacokinetics and pharmacodynamics2026
Construction of a translational whole-body physiologically based pharmacokinetic model to investigate the biodistribution of lipid nanoparticle-based mRNA therapeutics for intracellular protein targets.
Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticle (LNP)-based messenger RNA (mRNA) therapeutics enable in vivo production of diverse protein modalities, but their translation is complicated by multiscale pharmacokinetics encompassing tissue transport, cellular uptake, and intracellular processing. We developed a platform translational whole-body physiologically based pharmacokinetic (PBPK) model to mechanistically characterize the biodistribution and protein expression of intravenously administered mRNA-LNP therapeutics. The model integrates receptor-mediated, saturable tissue infiltration, lymphatic recirculation, hepatic uptake, and explicit intracellular processes including endosomal degradation, mRNA escape, translation, and protein turnover. Parameters were calibrated using comprehensive rat biodistribution data containing both tissue-level mRNA and translated protein measurements, enabling characterization of rapid early tissue deposition and dominant hepatic protein production. Sensitivity analyses identified endosomal degradation, mRNA stability, and translation efficiency as the primary determinants of hepatic protein exposure, whereas increasing tissue influx alone yielded minimal effect. Using fundamental allometric scaling principle, the model was translated from rat to human and evaluated against published clinical plasma mRNA pharmacokinetics of an mRNA-encoded monoclonal antibody. Virtual population simulations reproduced dose-dependent peak timing and clearance across multiple dosing regimens. Cell-type specific simulation analyses further demonstrated the competing roles of Kupffer cells and hepatocytes in shaping liver protein exposure. This whole-body PBPK framework provides a mechanistic and predictive platform to support first-in-human dose selection, to interrogate multilevel determinants of mRNA pharmacokinetics, and to guide rational mRNA-LNP design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.